Anchored in work undertaken and patented by researchers at Duke University, Annias Immunotherapeutics, Inc. is a clinical stage immuno-oncology company focused on the development of novel immunotherapeutic approaches to the treatment of cancers that containing Cytomegalovirus (CMV). The approach is to harness the bodyâs immune system to recognize, attack and destroy tumor cells containing CMV. CMV is over-expressed in a variety of human cancers including significant and homogeneous expression in almost all glioblastoma, but not in normal brain tissue. Annias Immunotherapeutics focuses on this opportunity to use CMV proteins as tumor-specific targets.Annias Immunotherapeutics, Inc. is a clinical stage immuno-oncology company focused on the development of novel immunotherapeutic approaches harnessing the bodyâs immune system to recognize, attack and destroy tumor cells containing CM
